同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识(2023版)

Chinese experts'consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy(2023 version)

中性粒细胞减少症是恶性肿瘤患者同步放化疗期间最常见的血液学毒性,导致后续治疗延迟和(或)剂量减少,易引发中性粒细胞减少性发热及严重感染,影响患者预后及安全。合理预防和管理恶性肿瘤患者同步放化疗期间的中性粒细胞减少症至关重要。聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)作为重组人粒细胞刺激因子的长效制剂,可预防和治疗中性粒细胞减少症,临床使用更加便捷。为促进临床合理用药,中国医师协会放射肿瘤治疗医师分会、中华医学会放射肿瘤治疗学分会、中国抗癌协会肿瘤放射治疗专业委员会参考PEG-rhG-CSF相关指南及最新循证证据,评估其在同步放化疗期间应用的有效性及安全性,明确预防与治疗的临床路径及给药方式,形成同步放化疗期间应用PEG-rhG-CSF中国专家共识。

Neutropenia is the most common hematologic toxicity of concurrent chemoradiotherapy for malignant tumor patients,which can lead to follow-up treatment delay and/or dose reduction,induce febrile neutropenia and severe infection easily,thus affecting prognosis and safety of patients.It is important to prevent and manage neutropenia in patients with malignant tumors during concurrent chemoradiotherapy reasonably.As a long-acting preparation of recombinant human granulocyte colony-stimulating factor,pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)can prevent and treat neutropenia,which is more convenient for clinical practice.In order to promote clinical rational administration of drugs,Radiation Oncology Treatment Physician Branch of Chinese Medical Doctor Association,Radiation Oncology Therapy Branch of Chinese Medical Association,Chinese Association of Radiation Therapy of China Anti-Cancer Association consulted guidelines and the latest evidence-based evidences related to PEG-rhG-CSF,evaluated the effectiveness and safety of the application of PEG-rhG-CSF during concurrent chemoradiotherapy,clarified the clinical pathway and administration route of prevention and treatment and then formed a Chinese experts'consensus on the application of PEG-rhG-CSF during concurrent chemoradiotherapy.